US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Zenas BioPharma Inc.

31.65

-0.6400-1.98%

Post-market: 31.39-0.2600-0.82%18:18 EDT

Volume:481.87K

Turnover:15.24M

Market Cap:2.06B

PE:-3.50

High:32.48

Open:32.40

Low:30.95

Close:32.29

52wk High:44.60

52wk Low:13.50

Shares:65.18M

Float Shares:39.84M

Volume Ratio:0.41

T/O Rate:1.21%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-9.0522

EPS(LYR):-8.4448

ROE:-199.04%

ROA:-34.42%

PB:8.35

PE(LYR):-3.75

Loading ...

Overview Company News Filings

Zenas Biopharma posts corporate presentation on autoimmune disease pipeline, led by obexelimab

Zenas BioPharma doses first subject in Phase 1 trial of oral IL-17 inhibitor ZB021

Zenas Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of Zb021, a Novel, Potentially Best-in-Class Oral Il-17Aa/Af Inhibitor

THOMSON REUTERS

InnoCare Pharma starts Phase 1 trial of oral IL-17 inhibitor ICP-054 (ZB021)

Zenas BioPharma Highlights Strong Q1 Progress and Financing

Zenas BioPharma Q1 Net Loss Widens

MT Newswires Live

Zenas BioPharma reports Q1 EPS ($1.46) vs. (80c) last year

Earnings Flash (ZBIO) Zenas BioPharma Posts Q1 Net Loss $1.46 a Share, vs. FactSet Est of $1.47 Loss

MT Newswires Live

Zenas BioPharma Q1 FY26 net loss widens to $81 million; revenue falls to no revenue

Zenas Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS

Press Release: Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

A Look At Zenas BioPharma (ZBIO) Valuation After Obexelimab Trial Success And US$300 Million Fundraising

Simply Wall St.

Zenas BioPharma CEO Makes Bold Move With Major Personal Stock Buy

Zenas BioPharma CEO Leon Moulder acquires 60,000 shares worth $1.07 million

InnoCare Pharma Q1 net profit jumps to RMB 102.4 million; revenue rises 38.7% to RMB 528.6 million

Zenas BioPharma grants 41,475 inducement RSUs to new hires under 2026 plan

Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Morgan Stanley Reaffirms Their Hold Rating on Zenas BioPharma, Inc. (ZBIO)

Zenas Biopharma director Hongbo Lu acquires ZBIO common shares worth $0.1 million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/ZBIO/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ZBIO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZBIO\",,,,,undefined,":{"symbol":"ZBIO","market":"US","secType":"STK","nameCN":"Zenas BioPharma Inc.","latestPrice":31.65,"timestamp":1787601600000,"preClose":32.29,"halted":0,"volume":481866,"hourTrading":{"tag":"盘后","latestPrice":31.39,"preClose":31.65,"latestTime":"18:18 EDT","volume":27895,"amount":882865.508315,"timestamp":1787609907054,"change":-0.26,"changeRate":-0.008215,"amplitude":0.02812},"delay":0,"changeRate":-0.019820377825952324,"floatShares":39841600,"shares":65176700,"eps":-9.052203,"marketStatus":"Post-Mkt","change":-0.64,"latestTime":"08-24 18:22:35 EDT","open":32.4,"high":32.48,"low":30.95,"amount":15244507.449864,"amplitude":0.047383,"askPrice":32.6,"askSize":80,"bidPrice":25.61,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-9.052203,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787616000000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":32.29,"sharesOutstanding":249967,"nav":10.0592,"aum":2514468.0464,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":32.29,"preClose":32.29,"latestTime":"08:19 EDT","volume":2,"amount":64.57,"timestamp":1787573977491,"change":0,"changeRate":0,"amplitude":0.00031},"postHourTrading":{"tag":"盘后","latestPrice":31.39,"preClose":31.65,"latestTime":"18:18 EDT","volume":27895,"amount":882865.508315,"timestamp":1787609907054,"change":-0.26,"changeRate":-0.008215,"amplitude":0.02812},"volumeRatio":0.412985,"impliedVol":0.658,"impliedVolPercentile":0.1514},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZBIO\",,,,,undefined,":{"symbol":"ZBIO","floatShares":39841600,"roa":"-34.42%","roe":"-199.04%","lyrEps":-8.444814,"volumeRatio":0.412985,"shares":65176700,"dividePrice":0,"high":32.48,"amplitude":0.047383,"preClose":32.29,"low":30.95,"week52Low":13.5,"pbRate":"8.35","psRate":"2062.84","week52High":44.6,"institutionHeld":0,"latestPrice":31.65,"committee":0.111111,"eps":-9.052203,"divideRate":0,"volume":481866,"delay":0,"ttmEps":-9.052203,"open":32.4,"prevYearClose":36.31,"prevWeekClose":32.29,"prevMonthClose":31.44,"prevQuarterClose":25.38,"fiveDayClose":30.5,"twentyDayClose":32.82,"sixtyDayClose":18.56},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ZBIO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"ZBIO","fiscalQuarterEnding":"2026/06","expectedEps":-0.89,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"pre","actualEps":-1.77},{"market":"US","date":"2026-05-13","symbol":"ZBIO","fiscalQuarterEnding":"2026/03","expectedEps":-1.37,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778644800000,"reportTimeType":"pre","actualEps":-1.46},{"market":"US","date":"2026-03-16","symbol":"ZBIO","fiscalQuarterEnding":"2025/12","expectedEps":-1.22,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1773633600000,"reportTimeType":"pre","actualEps":-4.54},{"market":"US","date":"2025-11-12","symbol":"ZBIO","fiscalQuarterEnding":"2025/09","expectedEps":-0.87,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"pre","actualEps":-1.22},{"market":"US","date":"2025-08-12","symbol":"ZBIO","fiscalQuarterEnding":"2025/06","expectedEps":-1.02,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"pre","actualEps":-1.25}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ZBIO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ZBIO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.625,"buy":0.25,"hold":0.125,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.625,"analysts":8,"updateTime":1767758400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ZBIO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ZBIO","date":"2026-08-21","current":-3.493072,"percent":0.421488,"low":-19.592941,"twenty":-7.371525,"median":-3.831007,"eighty":-2.614149,"high":-1.802568,"avg":-5.311132,"sd":3.731751,"marketCap":2060887981},"quantilePoints":[{"date":"2024-09-13","current":-8.364044,"twenty":-11.189626,"median":-10.130033,"eighty":-9.07044,"marketCap":457989962},{"date":"2024-09-20","current":-12.731934,"twenty":-12.968841,"median":-12.731934,"eighty":-9.523082,"marketCap":697162515},{"date":"2024-09-27","current":-12.564791,"twenty":-13.484804,"median":-12.909978,"eighty":-12.029776,"marketCap":688010267},{"date":"2024-10-04","current":-14.275075,"twenty":-13.747873,"median":-12.811872,"eighty":-12.31335,"marketCap":781660299},{"date":"2024-10-11","current":-13.008553,"twenty":-13.941177,"median":-13.027627,"eighty":-12.397648,"marketCap":712309358},{"date":"2024-10-18","current":-16.373229,"twenty":-14.273549,"median":-13.29848,"eighty":-12.477586,"marketCap":896548905},{"date":"2024-10-25","current":-17.845752,"twenty":-15.022781,"median":-13.503182,"eighty":-12.59822,"marketCap":977179818},{"date":"2024-10-31","current":-16.022265,"twenty":-16.022265,"median":-13.891034,"eighty":-12.731934,"marketCap":877331175},{"date":"2024-11-08","current":-15.961228,"twenty":-15.961228,"median":-14.267446,"eighty":-12.811872,"marketCap":873988961},{"date":"2024-11-15","current":-6.06727,"twenty":-16.022265,"median":-14.202594,"eighty":-12.564791,"marketCap":782495852},{"date":"2024-11-22","current":-3.382919,"twenty":-15.961228,"median":-13.807463,"eighty":-11.896022,"marketCap":436298426},{"date":"2024-11-29","current":-3.729636,"twenty":-15.955124,"median":-13.496851,"eighty":-6.578437,"marketCap":481014835},{"date":"2024-12-06","current":-3.402361,"twenty":-15.898664,"median":-13.178717,"eighty":-4.851473,"marketCap":438805888},{"date":"2024-12-13","current":-2.997318,"twenty":-15.744546,"median":-13.008553,"eighty":-3.729636,"marketCap":386567092},{"date":"2024-12-20","current":-3.162575,"twenty":-15.636205,"median":-12.771903,"eighty":-3.606503,"marketCap":407880521},{"date":"2024-12-27","current":-3.256545,"twenty":-15.585849,"median":-12.510288,"eighty":-3.394584,"marketCap":419999921},{"date":"2025-01-03","current":-2.91955,"twenty":-15.427152,"median":-12.339512,"eighty":-3.24488,"marketCap":376537243},{"date":"2025-01-10","current":-3.007039,"twenty":-15.189107,"median":-10.412935,"eighty":-3.188498,"marketCap":387820823},{"date":"2025-01-17","current":-2.520987,"twenty":-15.022781,"median":-6.676265,"eighty":-3.159983,"marketCap":325134267},{"date":"2025-01-24","current":-2.715408,"twenty":-14.870188,"median":-6.06727,"eighty":-3.071846,"marketCap":350208890},{"date":"2025-01-31","current":-2.469142,"twenty":-14.351372,"median":-4.794107,"eighty":-2.968155,"marketCap":318447701},{"date":"2025-02-07","current":-2.54367,"twenty":-14.313224,"median":-3.888412,"eighty":-2.841781,"marketCap":328059640},{"date":"2025-02-14","current":-2.313605,"twenty":-14.275075,"median":-3.716674,"eighty":-2.653842,"marketCap":298388004},{"date":"2025-02-21","current":-2.530708,"twenty":-14.268972,"median":-3.643766,"eighty":-2.622086,"marketCap":326387998},{"date":"2025-02-28","current":-2.141867,"twenty":-14.163683,"median":-3.476889,"eighty":-2.54367,"marketCap":276238754},{"date":"2025-03-07","current":-2.35573,"twenty":-14.007233,"median":-3.332693,"eighty":-2.517747,"marketCap":303820838},{"date":"2025-03-14","current":-2.324434,"twenty":-13.840892,"median":-3.246824,"eighty":-2.465902,"marketCap":364908203},{"date":"2025-03-21","current":-2.26852,"twenty":-13.569102,"median":-3.188498,"eighty":-2.360915,"marketCap":356130342},{"date":"2025-03-28","current":-2.138053,"twenty":-13.499383,"median":-3.165816,"eighty":-2.351842,"marketCap":335648668},{"date":"2025-04-04","current":-2.076814,"twenty":-13.408148,"median":-3.159335,"eighty":-2.284767,"marketCap":326034820},{"date":"2025-04-11","current":-1.80523,"twenty":-13.315978,"median":-3.071846,"eighty":-2.26652,"marketCap":283399498},{"date":"2025-04-17","current":-2.21793,"twenty":-13.154764,"median":-2.997318,"eighty":-2.257224,"marketCap":348188468},{"date":"2025-04-25","current":-2.657256,"twenty":-13.051602,"median":-2.943853,"eighty":-2.261324,"marketCap":417157373},{"date":"2025-05-02","current":-3.077944,"twenty":-13.023813,"median":-2.968155,"eighty":-2.26639,"marketCap":483200324},{"date":"2025-05-09","current":-2.4756,"twenty":-13.008271,"median":-2.943853,"eighty":-2.269325,"marketCap":388639550},{"date":"2025-05-16","current":-2.503456,"twenty":-12.890356,"median":-2.890387,"eighty":-2.270833,"marketCap":407464932},{"date":"2025-05-23","current":-2.942974,"twenty":-12.763909,"median":-2.866084,"eighty":-2.272453,"marketCap":479001383},{"date":"2025-05-30","current":-2.570283,"twenty":-12.665077,"median":-2.835832,"eighty":-2.278934,"marketCap":418341820},{"date":"2025-06-06","current":-2.470042,"twenty":-12.521189,"median":-2.721889,"eighty":-2.297829,"marketCap":402026489},{"date":"2025-06-13","current":-2.90956,"twenty":-12.426717,"median":-2.835832,"eighty":-2.31327,"marketCap":473562940},{"date":"2025-06-20","current":-2.392933,"twenty":-12.365673,"median":-2.76689,"eighty":-2.315238,"marketCap":389476234},{"date":"2025-06-27","current":-2.608837,"twenty":-12.215932,"median":-2.714219,"eighty":-2.322158,"marketCap":424616947},{"date":"2025-07-03","current":-2.577994,"twenty":-11.896022,"median":-2.691086,"eighty":-2.323707,"marketCap":419596845},{"date":"2025-07-11","current":-3.102331,"twenty":-8.929847,"median":-2.679496,"eighty":-2.324434,"marketCap":504938576},{"date":"2025-07-18","current":-3.387633,"twenty":-8.364044,"median":-2.699206,"eighty":-2.336288,"marketCap":551374518},{"date":"2025-07-25","current":-4.194702,"twenty":-6.676265,"median":-2.718649,"eighty":-2.349239,"marketCap":682733850},{"date":"2025-08-01","current":-4.037914,"twenty":-6.187126,"median":-2.829882,"eighty":-2.35573,"marketCap":657214999},{"date":"2025-08-08","current":-3.804019,"twenty":-6.06727,"median":-2.865865,"eighty":-2.35573,"marketCap":619145893},{"date":"2025-08-15","current":-3.987237,"twenty":-5.542498,"median":-2.90956,"eighty":-2.36209,"marketCap":705768845},{"date":"2025-08-22","current":-4.02768,"twenty":-4.889717,"median":-2.928692,"eighty":-2.362211,"marketCap":712927599},{"date":"2025-08-29","current":-3.868286,"twenty":-4.698498,"median":-2.950685,"eighty":-2.372371,"marketCap":684713689},{"date":"2025-09-05","current":-4.039575,"twenty":-4.396216,"median":-2.982091,"eighty":-2.374493,"marketCap":715033114},{"date":"2025-09-12","current":-4.798483,"twenty":-4.881439,"median":-2.99503,"eighty":-2.389351,"marketCap":849365013},{"date":"2025-09-19","current":-4.629572,"twenty":-4.881439,"median":-3.063777,"eighty":-2.399463,"marketCap":819466690},{"date":"2025-09-26","current":-4.429735,"twenty":-4.835595,"median":-3.074895,"eighty":-2.402603,"marketCap":784094028},{"date":"2025-10-03","current":-4.984046,"twenty":-4.911724,"median":-3.083269,"eighty":-2.409912,"marketCap":882211057},{"date":"2025-10-10","current":-6.604159,"twenty":-5.180553,"median":-3.135974,"eighty":-2.413574,"marketCap":1168982288},{"date":"2025-10-17","current":-5.759607,"twenty":-5.320916,"median":-3.162575,"eighty":-2.420654,"marketCap":1019490677},{"date":"2025-10-24","current":-5.949928,"twenty":-5.76722,"median":-3.174048,"eighty":-2.42495,"marketCap":1053178928},{"date":"2025-10-31","current":-9.035303,"twenty":-6.083769,"median":-3.188498,"eighty":-2.432369,"marketCap":1599311910},{"date":"2025-11-07","current":-9.81546,"twenty":-6.198298,"median":-3.245204,"eighty":-2.444339,"marketCap":1737405107},{"date":"2025-11-14","current":-10.08009,"twenty":-6.457611,"median":-3.282468,"eighty":-2.446909,"marketCap":1914199059},{"date":"2025-11-21","current":-9.848299,"twenty":-7.258864,"median":-3.371139,"eighty":-2.451734,"marketCap":1870182143},{"date":"2025-11-28","current":-10.976161,"twenty":-8.972029,"median":-3.394997,"eighty":-2.453948,"marketCap":2084362015},{"date":"2025-12-05","current":-10.772637,"twenty":-9.459248,"median":-3.515773,"eighty":-2.459247,"marketCap":2045713016},{"date":"2025-12-12","current":-11.366249,"twenty":-9.83041,"median":-3.643766,"eighty":-2.466418,"marketCap":2158439264},{"date":"2025-12-19","current":-9.913314,"twenty":-9.980024,"median":-3.678075,"eighty":-2.469682,"marketCap":1882528351},{"date":"2025-12-26","current":-12.202958,"twenty":-10.134363,"median":-3.729636,"eighty":-2.472265,"marketCap":2317329596},{"date":"2026-01-02","current":-10.263827,"twenty":-10.232168,"median":-3.760324,"eighty":-2.476253,"marketCap":1949090517},{"date":"2026-01-09","current":-4.638651,"twenty":-10.207521,"median":-3.79333,"eighty":-2.479511,"marketCap":880875114},{"date":"2026-01-16","current":-5.633657,"twenty":-10.159019,"median":-3.831007,"eighty":-2.483289,"marketCap":1069825778},{"date":"2026-01-23","current":-5.766513,"twenty":-10.142278,"median":-3.88256,"eighty":-2.488034,"marketCap":1095054986},{"date":"2026-01-30","current":-5.902195,"twenty":-10.122491,"median":-3.950232,"eighty":-2.490604,"marketCap":1120820986},{"date":"2026-02-06","current":-5.938943,"twenty":-10.119664,"median":-3.975342,"eighty":-2.498305,"marketCap":1127799277},{"date":"2026-02-13","current":-7.380571,"twenty":-10.08009,"median":-4.008147,"eighty":-2.503456,"marketCap":1401563024},{"date":"2026-02-20","current":-7.637803,"twenty":-9.946669,"median":-4.026371,"eighty":-2.50452,"marketCap":1450411065},{"date":"2026-02-27","current":-7.451239,"twenty":-9.897484,"median":-4.035344,"eighty":-2.514003,"marketCap":1414982815},{"date":"2026-03-06","current":-7.140299,"twenty":-9.857345,"median":-4.041954,"eighty":-2.520051,"marketCap":1355935733},{"date":"2026-03-13","current":-6.925469,"twenty":-9.824447,"median":-4.068124,"eighty":-2.528764,"marketCap":1315139567},{"date":"2026-03-20","current":-3.549457,"twenty":-9.816065,"median":-4.041954,"eighty":-2.535893,"marketCap":1340761298},{"date":"2026-03-27","current":-3.365681,"twenty":-9.764845,"median":-4.035344,"eighty":-2.542374,"marketCap":1271342335},{"date":"2026-04-02","current":-3.206266,"twenty":-9.752191,"median":-4.02768,"eighty":-2.54367,"marketCap":1211125146},{"date":"2026-04-10","current":-3.351146,"twenty":-9.585134,"median":-4.008147,"eighty":-2.555011,"marketCap":1265851823},{"date":"2026-04-17","current":-3.426736,"twenty":-9.459248,"median":-3.975342,"eighty":-2.562572,"marketCap":1294404871},{"date":"2026-04-24","current":-2.91178,"twenty":-9.318941,"median":-3.950232,"eighty":-2.56484,"marketCap":1099887227},{"date":"2026-05-01","current":-3.042488,"twenty":-9.220114,"median":-3.88256,"eighty":-2.568711,"marketCap":1149260207},{"date":"2026-05-08","current":-3.034614,"twenty":-9.118797,"median":-3.818719,"eighty":-2.573367,"marketCap":1146285931},{"date":"2026-05-15","current":-2.806581,"twenty":-9.04377,"median":-3.782641,"eighty":-2.576966,"marketCap":1193220825},{"date":"2026-05-22","current":-2.946168,"twenty":-8.972029,"median":-3.74498,"eighty":-2.576966,"marketCap":1252566199},{"date":"2026-05-29","current":-2.756092,"twenty":-8.703526,"median":-3.716674,"eighty":-2.577994,"marketCap":1171755477},{"date":"2026-06-05","current":-2.729363,"twenty":-8.073548,"median":-3.672934,"eighty":-2.577994,"marketCap":1160391469},{"date":"2026-06-12","current":-2.637295,"twenty":-7.609535,"median":-3.597675,"eighty":-2.580331,"marketCap":1121248775},{"date":"2026-06-18","current":-2.759062,"twenty":-7.566764,"median":-3.544789,"eighty":-2.584211,"marketCap":1173018144},{"date":"2026-06-26","current":-3.663405,"twenty":-7.560564,"median":-3.528998,"eighty":-2.58741,"marketCap":1557500410},{"date":"2026-07-02","current":-4.157898,"twenty":-7.541694,"median":-3.549457,"eighty":-2.594231,"marketCap":1767734556},{"date":"2026-07-10","current":-4.370248,"twenty":-7.462546,"median":-3.643766,"eighty":-2.595516,"marketCap":1858015285},{"date":"2026-07-17","current":-4.193537,"twenty":-7.451239,"median":-3.672934,"eighty":-2.596017,"marketCap":1782886566},{"date":"2026-07-24","current":-4.601902,"twenty":-7.448412,"median":-3.716674,"eighty":-2.598756,"marketCap":1956503353},{"date":"2026-07-31","current":-4.791978,"twenty":-7.400923,"median":-3.74498,"eighty":-2.598756,"marketCap":2037314075},{"date":"2026-08-07","current":-4.777128,"twenty":-7.389051,"median":-3.770746,"eighty":-2.606821,"marketCap":2031000738},{"date":"2026-08-14","current":-3.929032,"twenty":-7.382267,"median":-3.79905,"eighty":-2.610296,"marketCap":1903160311},{"date":"2026-08-21","current":-4.254657,"twenty":-7.371525,"median":-3.831007,"eighty":-2.614149,"marketCap":2060887981}],"updateTime":1787586722585},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ZBIO\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2635786747","title":"Zenas Biopharma posts corporate presentation on autoimmune disease pipeline, led by obexelimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2635786747","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635786747?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:12","pubTimestamp":1778670742,"startTime":"0","endTime":"0","summary":"Zenas Biopharma outlined plans for global marketing submissions for obexelimab in IgG4-related disease, with FDA BLA filing targeted for Q2 2026 and EMA MAA filing targeted for H2 2026.Phase 3 INDIGO trial in IgG4-RD met primary endpoint, cutting flare risk 56% versus placebo ; 73% of treated patients remained flare-free through week 52.Safety profile in INDIGO showed serious adverse events at 10% versus 19% for placebo; grade 3 infections ran 2% versus 4%.Multiple sclerosis program orelabrutinib advanced with Phase 3 trials initiated in PPMS in Q3 2025 and naSPMS in Q1 2026.Pipeline updates included Phase 2 SLE topline data for obexelimab expected in Q4 2026; early-stage assets ZB021, ZB022, ZB014 guided to initial clinical readouts from late 2026 into 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL91ZBd8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635785125","title":"Zenas BioPharma doses first subject in Phase 1 trial of oral IL-17 inhibitor ZB021","url":"https://stock-news.laohu8.com/highlight/detail?id=2635785125","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635785125?lang=en_us&edition=fundamental","pubTime":"2026-05-13 18:50","pubTimestamp":1778669427,"startTime":"0","endTime":"0","summary":"Zenas Biopharma dosed first subject in a Phase 1 study of ZB021, an oral IL-17AA/AF inhibitor, marking start of human testing for program aimed at autoimmune and inflammatory diseases.Trial will assess safety, tolerability, pharmacokinetics in healthy volunteers, then support a proof-of-concept readout in plaque psoriasis.Single-ascending-dose and multiple-ascending-dose results are scheduled for release by year-end 2026, with psoriasis proof-of-concept data expected in 2027.Development plan targets a potential move from proof-of-concept into registration-directed trials, which could shorten timeline to a pivotal program if early data support the approach.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL2qPtX9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","SG9999014021.USD","IE00BN0W2W23.USD","BK4112","LU2095319765.USD","SG9999014005.SGD","IE00BN0W2V16.EUR","SG9999014013.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","LU2210150020.SGD","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4139","BK4588","LU2210149790.SGD","BK4585","ZBIO","NDAQ","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635978513","title":"Zenas Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of Zb021, a Novel, Potentially Best-in-Class Oral Il-17Aa/Af Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2635978513","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635978513?lang=en_us&edition=fundamental","pubTime":"2026-05-13 18:50","pubTimestamp":1778669400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nTUA7N9WRF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635785572","title":"InnoCare Pharma starts Phase 1 trial of oral IL-17 inhibitor ICP-054 (ZB021)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635785572","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635785572?lang=en_us&edition=fundamental","pubTime":"2026-05-13 18:46","pubTimestamp":1778669181,"startTime":"0","endTime":"0","summary":"InnoCare Pharma reported first patient enrolled in Phase 1 trial of oral IL-17AA/AF inhibitor ICP-054 , marking start of human testing.No results have been presented; study will assess safety, tolerability, pharmacokinetics in healthy volunteers to support later proof-of-concept work in autoimmune diseases.Program sits within October 2025 licensing deal granting Zenas BioPharma exclusive rights to develop, manufacture, commercialize ICP-054 outside Greater China and Southeast Asia, with Phase 1 work conducted in China in collaboration with Zenas.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL8ZppzB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139","BK0239","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635278302","title":"Zenas BioPharma Highlights Strong Q1 Progress and Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2635278302","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635278302?lang=en_us&edition=fundamental","pubTime":"2026-05-13 18:34","pubTimestamp":1778668493,"startTime":"0","endTime":"0","summary":"The latest update is out from Zenas BioPharma, Inc. ( ($ZBIO) ). On May 11, 2026, Zenas BioPharma stockholders approved two Class II directors for ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/zenas-biopharma-highlights-strong-q1-progress-and-financing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/zenas-biopharma-highlights-strong-q1-progress-and-financing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2065732104.USD","BK4139","ZBIO","BK4097","PRGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635788477","title":"Zenas BioPharma Q1 Net Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2635788477","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635788477?lang=en_us&edition=fundamental","pubTime":"2026-05-13 18:16","pubTimestamp":1778667413,"startTime":"0","endTime":"0","summary":"Zenas BioPharma  reported a Q1 net loss Wednesday of $1.46 per diluted share, widening from a loss of $0.80 a year earlier.Analysts surveyed by FactSet expected a loss of $1.47.The company didn't produce any revenue for the quarter ended Mar. 31, compared with $10,000 a year earlier.Analysts polled by FactSet expected no sales.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635887717","title":"Zenas BioPharma reports Q1 EPS ($1.46) vs. (80c) last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2635887717","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635887717?lang=en_us&edition=fundamental","pubTime":"2026-05-13 18:15","pubTimestamp":1778667357,"startTime":"0","endTime":"0","summary":"Reports Q1 revenue $0 vs. $10M last year. As of March 31 the Company’s cash, cash equivalents and investments were $718.5M. “This quarter we contin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zenas-biopharma-reports-q1-eps-1-46-vs-80c-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zenas-biopharma-reports-q1-eps-1-46-vs-80c-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635883107","title":"Earnings Flash (ZBIO) Zenas BioPharma Posts Q1 Net Loss $1.46 a Share, vs. FactSet Est of $1.47 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2635883107","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635883107?lang=en_us&edition=fundamental","pubTime":"2026-05-13 18:04","pubTimestamp":1778666671,"startTime":"0","endTime":"0","summary":"Earnings Flash (ZBIO) Zenas BioPharma Posts Q1 Net Loss $1.46 a Share, vs. FactSet Est of $1.47 Loss","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635200725","title":"Zenas BioPharma Q1 FY26 net loss widens to $81 million; revenue falls to no revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2635200725","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635200725?lang=en_us&edition=fundamental","pubTime":"2026-05-13 18:01","pubTimestamp":1778666500,"startTime":"0","endTime":"0","summary":"Zenas Biopharma posted a wider Q1 net loss of USD 81 million, with loss per share widening to USD 1.46.Operating loss widened to USD 77.35 million as R&D expenses climbed 73% to USD 60.44 million.G&A expenses increased 36% to USD 16.91 million, while other expense swung to USD 3.64 million from other income a year earlier.Cash, cash equivalents and investments rose to USD 718.55 million; cash runway extended into 2029 following USD 419 million in gross proceeds raised year to date and a new up to USD 250 million senior secured debt facility.Obexelimab IgG4-RD BLA submission remains on track for this quarter, with EMA filing planned for H2 2026; Phase 2 SunStone SLE enrollment completed with topline results expected in Q4 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL875M3X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2095319765.USD","BK4588","IE00B64PRP62.GBP","SG9999014005.SGD","NDAQ","SG9999014021.USD","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","LU2210150020.SGD","IE00BKPKM429.USD","IE00BGHQF748.EUR","SG9999014039.USD","LU0314104364.USD","IE00B3QW5Z07.USD","LU2210149790.SGD","SG9999014013.SGD","BK4139","ZBIO","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635200905","title":"Zenas Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635200905","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635200905?lang=en_us&edition=fundamental","pubTime":"2026-05-13 18:00","pubTimestamp":1778666401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nTUABVQ4RF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635200456","title":"Press Release: Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635200456","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635200456?lang=en_us&edition=fundamental","pubTime":"2026-05-13 18:00","pubTimestamp":1778666400,"startTime":"0","endTime":"0","summary":"-- Obexelimab marketing applications for the treatment of IgG4-RD on-target for submission to the FDA this quarter and the EMA in H2 2026 based on the Phase 3 INDIGO IgG4-RD trial results --. -- Obexelimab Phase 3 INDIGO IgG4-RD trial results accepted for oral presentation at EULAR 2026 --. -- Obexelimab global Phase 2 SunStone SLE trial enrollment complete; topline results expected in Q4 2026 --. -- First subject dosed in Phase 1 trial of ZB021 ; initial clinical data expected by year-end --. -- Orelabrutinib global Phase 3 PriMroSe trial in patients with PPMS and global Phase 3 Monarch trial in patients with naSPMS ongoing --. -- Completed public offerings and entered into debt financing; cash runway extended into 2029 --. WALTHAM, Mass., May 13, 2026  -- Zenas BioPharma, Inc.  , a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today reported","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4215","ZBIO","MAA","BK4077","SLE","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632904933","title":"A Look At Zenas BioPharma (ZBIO) Valuation After Obexelimab Trial Success And US$300 Million Fundraising","url":"https://stock-news.laohu8.com/highlight/detail?id=2632904933","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632904933?lang=en_us&edition=fundamental","pubTime":"2026-05-04 13:14","pubTimestamp":1777871650,"startTime":"0","endTime":"0","summary":"Zenas BioPharma (ZBIO) is in focus after reporting Phase 2 data showing its multiple sclerosis candidate obexelimab achieved a 95% reduction in brain lesions and announcing two concurrent public offerings raising US$300 million.\nSee our latest analysis for Zenas BioPharma.\nThe latest clinical and fundraising updates arrive after a volatile stretch, with the 1-year total shareholder return of 62.42% contrasting with a year-to-date share price return of negative 43.88%, while recent 7-day gains...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zbio/zenas-biopharma/news/a-look-at-zenas-biopharma-zbio-valuation-after-obexelimab-tr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zbio/zenas-biopharma/news/a-look-at-zenas-biopharma-zbio-valuation-after-obexelimab-tr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631728005","title":"Zenas BioPharma CEO Makes Bold Move With Major Personal Stock Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2631728005","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631728005?lang=en_us&edition=fundamental","pubTime":"2026-04-30 10:00","pubTimestamp":1777514454,"startTime":"0","endTime":"0","summary":"New insider activity at Zenas BioPharma, Inc. ( ($ZBIO) ) has taken place on April 29, 2026. Zenas BioPharma, Inc. has drawn investor attention aft...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/zenas-biopharma-ceo-makes-bold-move-with-major-personal-stock-buy-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/zenas-biopharma-ceo-makes-bold-move-with-major-personal-stock-buy-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631573377","title":"Zenas BioPharma CEO Leon Moulder acquires 60,000 shares worth $1.07 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2631573377","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631573377?lang=en_us&edition=fundamental","pubTime":"2026-04-30 07:21","pubTimestamp":1777504897,"startTime":"0","endTime":"0","summary":"Zenas BioPharma CEO Leon O. Moulder Jr. reported open-market purchases of common stock.Tellus BioVentures LLC acquired 60,000 shares at weighted average prices of $18.02, $17.62.Tellus BioVentures holdings rose to 1,786,039 shares held indirectly.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 29, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDLX49Tx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Zenas BioPharma CEO Leon Moulder acquires 60,000 shares worth $1.07 million","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629384638","title":"InnoCare Pharma Q1 net profit jumps to RMB 102.4 million; revenue rises 38.7% to RMB 528.6 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2629384638","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629384638?lang=en_us&edition=fundamental","pubTime":"2026-04-23 18:59","pubTimestamp":1776941982,"startTime":"0","endTime":"0","summary":"InnoCare Pharma posted Q1 2026 net profit of RMB 102.4 million, up 607.7% year over year.Revenue climbed 38.7% to RMB 528.6 million, driven by higher orelabrutinib volume, new contributions from tafasitamab and zurletrectinib, plus milestone payments from Zenas BioPharma.Operating profit jumped more than fivefold to RMB 104.5 million.R&D spending rose 10.4% to RMB 229.2 million, while cash and related account balances totaled about RMB 7.9 billion as of March 31.Management said it will continue accelerating pipeline development, aiming to sustain high-quality growth.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDL5T3xGz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK0239","BK4139","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628781018","title":"Zenas BioPharma grants 41,475 inducement RSUs to new hires under 2026 plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2628781018","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628781018?lang=en_us&edition=fundamental","pubTime":"2026-04-18 04:15","pubTimestamp":1776456941,"startTime":"0","endTime":"0","summary":"Zenas BioPharma granted 41,475 restricted stock units to newly hired employees on April 15, 2026 under its 2026 Inducement Plan.RSUs vest in four equal installments, with 25% scheduled on April 15 each year from 2027 through 2030.Awards require continued service through each vesting date.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nNDL24DyXB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00BN0W2W23.USD","BK4112","SG9999014039.USD","IE00BN0W2V16.EUR","BK4139","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","SG9999014005.SGD","LU2095319765.USD","SG9999014013.SGD","LU2210150020.SGD","ZBIO","SG9999014021.USD","IE00BKPKM429.USD","LU0314104364.USD","IE00BGHQF748.EUR","NDAQ","BK4585","BK4588","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628086781","title":"Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2628086781","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628086781?lang=en_us&edition=fundamental","pubTime":"2026-04-18 04:15","pubTimestamp":1776456900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nTUA8SJLP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628810717","title":"Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2628810717","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628810717?lang=en_us&edition=fundamental","pubTime":"2026-04-18 04:15","pubTimestamp":1776456900,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., April  17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in th","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/17/3276496/0/en/Zenas-BioPharma-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625497289","title":"Morgan Stanley Reaffirms Their Hold Rating on Zenas BioPharma, Inc. (ZBIO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2625497289","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625497289?lang=en_us&edition=fundamental","pubTime":"2026-04-08 20:36","pubTimestamp":1775651788,"startTime":"0","endTime":"0","summary":"In a report released today, Judah Frommer from Morgan Stanley maintained a Hold rating on Zenas BioPharma, Inc., with a price target of $21.00. Fro...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/morgan-stanley-reaffirms-their-hold-rating-on-zenas-biopharma-inc-zbio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/morgan-stanley-reaffirms-their-hold-rating-on-zenas-biopharma-inc-zbio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0106831901.USD","LU2347655156.SGD","IE00BKVL7J92.USD","LU0006306889.USD","LU0314104364.USD","LU1668664300.SGD","LU1363072403.SGD","LU0882574139.USD","LU1720051017.SGD","LU0557290698.USD","LU1074936037.SGD","LU1244550494.USD","LU2133065610.SGD","BK4504","LU2089284900.SGD","LU1548497426.USD","LU1244550577.SGD","BK4581","IE00BZ1G4Q59.USD","LU0225283273.USD","LU1791710400.SGD","LU2028103732.USD","LU1732800096.USD","LU0528227936.USD","LU0320765646.SGD","LU2023251221.USD","LU2111349929.HKD","BK4139","LU1791710582.SGD","LU0971096721.USD","LU1989772840.SGD","BK4127","LU0795875086.SGD","LU2089283258.USD","LU1720051108.HKD","LU0098860793.USD","LU2357305700.SGD","BK4588","LU1162221912.USD","LU1732799900.SGD","BK4585","LU1989772923.USD","LU2271345857.HKD","ZBIO","LU1244550221.USD","LU0795875169.SGD","LU0158827781.USD","LU0158827948.USD","BK4516","LU0912757837.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624687110","title":"Zenas Biopharma director Hongbo Lu acquires ZBIO common shares worth $0.1 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624687110","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624687110?lang=en_us&edition=fundamental","pubTime":"2026-04-03 05:03","pubTimestamp":1775163781,"startTime":"0","endTime":"0","summary":"Zenas BioPharma director Hongbo Lu reported an indirect purchase of 3,768 common shares at USD 18.63 each.Indirect beneficial ownership rose to 426,736 shares following the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 02, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL1ckfL3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Zenas Biopharma director Hongbo Lu acquires ZBIO common shares worth $0.1 million","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":4,"totalSize":109,"code":"91000000","status":"200"}]}}